Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know


Piper Sandler has decided to maintain its Overweight rating of Altimmune ALT and lower its price target from $34.00 to $25.00.

Shares of Altimmune are trading down 0.57% over the last 24 hours, at $5.26 per share.

A move to $25.00 would account for a 375.29% increase from the current share price.

About Altimmune

Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases. The firm's product candidates include NasoVAX, HepTcell, ALT-801, T-COVID, and NasoShield. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.



Analyst Ratings




Posted In: Analyst RatingsBZI-AAR-UPDATE